Multicenter Prospective Study for the Prediction of Drug-Resistant Pathogens in Hospitalized Patients with Community-Acquired Pneumonia and Healthcare-Associated Pneumonia in Japan (CJLSG 1205)
Not Applicable
- Conditions
- Community-Acquired Pneumonia (CAP) and Healthcare-Associated Pneumonia (HCAP)
- Registration Number
- JPRN-UMIN000009837
- Lead Sponsor
- Central Japan Lung Study Group
- Brief Summary
Infection and Drug Resistance; 11: 1703-1713, 2018
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 600
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients with obstructive pneumonia 2) Patients who do not receive initial empirical antibiotic treatment 3) Pneumonia that occurs 48 hours or more after admission 4) Patients who were transferred from other instructions and were already clinically improved 5) Patients who had been previously enrolled in this study
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Identified pathogens and drug resistance (especially which are not susceptible to beta-lactams, macrolides, and respiratory fluoroquinolones)
- Secondary Outcome Measures
Name Time Method 1) Presence or absence of serious illness and the time to develop 2) 30-day mortality and in-hospital mortality 3) Early and late treatment failure